JW Pharmaceutical Corp
KRX:001060
JW Pharmaceutical Corp
KRX:001060
Price:
32 200
KRW
3.87%
Market Cap:
₩767.6B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Posco International Corp
KRX:047050
|
KR |
JW Pharmaceutical Corp
Goodwill
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
JW Pharmaceutical Corp
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
JW Pharmaceutical Corp
KRX:001060
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Goodwill
₩115.1B
|
CAGR 3-Years
170%
|
CAGR 5-Years
292%
|
CAGR 10-Years
N/A
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Goodwill
₩1.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Goodwill
₩3.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
JW Pharmaceutical Corp
Glance View
JW PHARMACEUTICAL Corp. engages in the development, manufacture, and sale of pharmaceuticals. The company is headquartered in Seoul, Seoul. The firm mainly produces and sells drugs including supplying protein amino acids in blood, blood and fluid substitutes, hyperlipidemia agents, electrolyte additives, angina pectoris agents, rheumatoid arthritis drugs, perfusion fluid, prostatic hypertrophy drugs, hepatic coma drugs, and iron injections, among others. The firm also researches and develops anticancer drugs.
Intrinsic Value
47 281.54
KRW
Undervaluation 32%
